NCT01834235 - QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

March 13, 2017

Study Completion Date

December 31, 2019

Conditions

Pancreatic Cancer, Adult

Interventions

DRUG

Gemcitabine

Gemcitabine IV at a dose of 1000mg/m2 on days 1, 8, and 15 of a 4 week cycle.

DRUG

nab-paclitaxel

Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on Days 1, 7 and 15 for a 28 day cycle

DRUG

NPC-1C

NPC-1C(NEO-102) infusion at a dose of 1.5mg/kg IV on days 1 and 15 of a 28 day cycle. This will be administered 30 minutes after completion of the gemcitabine infusion.

Trial Locations (12)

19107

Thomas Jefferson University Hospital, Philadelphia

20892

National Cancer Institute, Bethesda

27599

University of North Carolina at Chapel Hill, Chapel Hill

27710

Duke University, Durham

33136

University of Miami, Miami

63110

Washington University in St. Louis, St Louis

75390

UT Southwestern Medical Center, Dallas

94115

California Pacific Medical Center, San Francisco

06510

Smilow Cancer Hospital- Yale, New Haven

02114

Massachusetts General Hospital, Boston

02215

Beht Isreal Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston